Research programme: protein serine threonine kinase inhibitors - Myrexis

Drug Profile

Research programme: protein serine threonine kinase inhibitors - Myrexis

Alternative Names: MPI-0485520; MPI-485520

Latest Information Update: 26 Nov 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis
  • Class Small molecules
  • Mechanism of Action I-kappa B kinase inhibitors; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Cancer; Inflammation; Rheumatoid arthritis

Highest Development Phases

  • Suspended Cancer; Diabetes mellitus; Inflammation; Obesity; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 11 May 2012 MPI 485520 is available for licensing (www.myrexis.com)
  • 26 May 2011 Preclinical trials in Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top